Soleno Therapeutics, Inc. Common Stock (SLNO)
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and neglected diseases. The company's primary focus has been on treatments for neurological and metabolic disorders, aiming to address unmet medical needs through innovative drug development.
Company News
Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders after a Scorpion Capital short report raised concerns about their Prader-Willi syndrome treatment, causing stock price decline.
Soleno Therapeutics reported its first commercial quarter with VYKAT XR for Prader-Willi syndrome, delivering $32.7 million in revenue, exceeding analyst expectations. The company showed promising early demand with 646 patient start forms and is preparing for potential European market entry.
Soleno Therapeutics, a medical device company, has entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock. The new funding option aims to bolster the company's financial flexibility and support its ongoing operations and strategic initiatives.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s jobs report on Friday. The S&P 500 rose 0.2% by midday trading in New York, following a 1% surge last Friday. Both the tech-heavy Nasdaq 100 and blue-chip stocks in the Dow Jones made similar gains. Small caps, as tracked by iShares Russell 2000 ETF (NYSE:IWM), outperformed large-cap stocks, rising as much as 0.9%. Tesla Inc. (NASDAQ:TSLA) grabbed the market spotlight by securing a significant partnership with Chinese search engine giant Baidu Inc. (NYSE:BIDU), which granted the Elon Musk-led company access to its mapping license for data collection on China’s public roads. The deal removes a last regulatory barrier for Tesla’s driver assistance system, known as Full Self-Driving (FSD), to be introduced in China. Shares of Tesla rose as much as 16% Monday. The Bank of Japan sent shockwaves through the ...Full story available on Benzinga.com
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
